Paracetamol Dc

This article summarizes several clinical trials investigating the use of Paracetamol DC, a common pain reliever and fever reducer, in various medical conditions. The trials explore its potential benefits and safety profile when used alone or in combination with other treatments for conditions ranging from multiple myeloma to lymphoma. While Paracetamol DC is not the primary focus of most trials, it is included as a supportive medication in some study protocols.

Table of Contents

Introduction

PARACETAMOL DC is a widely used medication that plays a crucial role in managing pain and fever. This article aims to provide patients with a comprehensive understanding of PARACETAMOL DC, its uses, benefits, and potential risks.

What is PARACETAMOL DC?

PARACETAMOL DC is a pharmaceutical formulation containing paracetamol, also known as acetaminophen. The “DC” in the name likely stands for “Direct Compression,” which refers to a specific manufacturing process used to produce the medication[1]. PARACETAMOL DC is part of a group of medications called analgesics (pain relievers) and antipyretics (fever reducers).

Medical Uses

PARACETAMOL DC is used to treat a variety of conditions, including:

  • Pain relief: It can help alleviate mild to moderate pain associated with headaches, toothaches, menstrual cramps, arthritis, backaches, and other types of pain[2].
  • Fever reduction: It is effective in reducing fever associated with various illnesses[2].
  • Auxiliary treatment in various medical conditions: PARACETAMOL DC is often used as a supportive treatment in conjunction with other medications for conditions such as:
    • Multiple myeloma[1]
    • Acute myocardial infarction (heart attack)[3]
    • Various types of cancer, including urothelial, cervical, ovarian, and prostate cancer[4]
    • Hodgkin and non-Hodgkin lymphoma[5]

Dosage and Administration

The dosage of PARACETAMOL DC can vary depending on the specific condition being treated and the patient’s individual needs. However, based on the available information from clinical trials, some general guidelines can be provided:

  • Typical daily dosage: The maximum daily dose generally ranges from 650 mg to 4000 mg[2][6].
  • Administration route: PARACETAMOL DC is usually taken orally, but in some cases, it may be administered intravenously[3].
  • Frequency: The medication can be taken as needed or on a regular schedule, depending on the doctor’s instructions.

It’s crucial to follow your healthcare provider’s instructions and never exceed the recommended dose, as overdosing on paracetamol can lead to severe liver damage.

Side Effects and Safety

While PARACETAMOL DC is generally considered safe when used as directed, it can cause side effects in some people. Common side effects may include:

  • Nausea
  • Stomach pain
  • Loss of appetite
  • Headache
  • Skin rash or itching

In rare cases, more serious side effects can occur. Seek immediate medical attention if you experience:

  • Signs of an allergic reaction (rash, itching, swelling, severe dizziness, difficulty breathing)
  • Signs of liver problems (persistent nausea/vomiting, loss of appetite, stomach/abdominal pain, yellowing eyes/skin, dark urine)

Precautions and Contraindications

Before taking PARACETAMOL DC, inform your doctor if you have:

  • Liver disease or a history of alcohol abuse
  • Kidney disease
  • Any allergies to medications

Pregnant and breastfeeding women should consult their healthcare provider before using PARACETAMOL DC[4].

Drug Interactions

PARACETAMOL DC may interact with other medications. It’s important to inform your healthcare provider about all the medications you’re taking, including prescription drugs, over-the-counter medicines, and herbal supplements. Some potential interactions include:

  • Warfarin (blood thinner)
  • Certain anti-epileptic medications
  • Medications that affect liver function

Ongoing Research

PARACETAMOL DC is being studied as an auxiliary treatment in various clinical trials, including:

  • A study on its use in combination with other medications for multiple myeloma[1]
  • Research on its role in managing pain and fever in patients with acute myocardial infarction[3]
  • Investigations into its supportive role in cancer treatments[4]
  • Studies on its use in lymphoma treatments[5][6]

These ongoing studies aim to further understand the potential benefits and optimal use of PARACETAMOL DC in various medical conditions.

Conclusion

PARACETAMOL DC is a versatile and widely used medication for pain relief and fever reduction. While it is generally safe when used as directed, it’s important to follow dosage instructions carefully and be aware of potential side effects and interactions. Always consult with your healthcare provider for personalized advice on using PARACETAMOL DC, especially if you have any underlying health conditions or are taking other medications.

Trial Focus Primary Condition Key Treatments Main Objectives
Multiple Myeloma Imaging Multiple Myeloma [68Ga]Ga-PentixaFor Evaluate sensitivity of [68Ga]Ga-PentixaFor-PET for detecting Multiple Myeloma lesions
Chronic Pain Treatment Diabetic Polyneuropathy AP707 Assess efficacy and safety of AP707 for chronic pain due to diabetic polyneuropathy
Myocardial Infarction Therapy Acute Myocardial Infarction Rituximab Evaluate effect of rituximab on left ventricular function after acute anterior STEMI
Solid Tumor Treatment Various Solid Tumors SKB264, Pembrolizumab Investigate safety and efficacy of SKB264 with pembrolizumab in solid tumors
Mantle Cell Lymphoma Therapy Mantle Cell Lymphoma Glofitamab Compare efficacy of glofitamab to standard treatments for relapsed/refractory MCL
Lymphoma Treatment Hodgkin and Non-Hodgkin Lymphoma GEN3017 Evaluate safety and efficacy of GEN3017 in relapsed/refractory lymphomas
Indolent Non-Hodgkin Lymphoma Therapy Indolent Non-Hodgkin Lymphoma Axicabtagene ciloleucel Assess efficacy of axicabtagene ciloleucel in relapsed/refractory iNHL

Ongoing Clinical Trials on Paracetamol Dc

  • Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1 1
    Investigated diseases:
    Belgium Denmark France Germany Greece Italy +3
  • Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

    Recruiting

    3 1 1 1
    Belgium Bulgaria Czechia Denmark France Germany +7
  • Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    France
  • Study on the Safety and Effectiveness of GEN3017 for Patients with Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Denmark France Germany Italy The Netherlands
  • Study on [68Ga]Ga-PentixaFor for Detecting Multiple Myeloma in Patients Under 66 Eligible for Stem Cell Transplantation

    Not recruiting

    2 1 1 1
    Investigated diseases:
    France
  • Study on the Effectiveness and Safety of AP707, Amitriptyline, and Capsaicin for Patients with Chronic Pain from Diabetic Neuropathy

    Not recruiting

    3 1 1
    Investigated diseases:
    Austria Germany
  • Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

    Not recruiting

    2 1 1 1
    Belgium France Poland Spain

Glossary

  • Paracetamol DC: A common pain reliever and fever reducer, also known as acetaminophen. The 'DC' likely refers to a specific formulation or manufacturing process.
  • Clinical trial: A research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease.
  • Multiple myeloma: A type of blood cancer that develops in plasma cells, a type of white blood cell that normally produces antibodies to help fight infections.
  • Diabetic polyneuropathy: A type of nerve damage that can occur in people with diabetes, often causing pain, tingling, or numbness in the extremities.
  • Myocardial infarction: Commonly known as a heart attack, it occurs when blood flow to part of the heart muscle is blocked, causing damage to the heart tissue.
  • Urothelial carcinoma: A type of cancer that typically occurs in the urinary system, including the bladder and related organs.
  • Lymphoma: A type of cancer that begins in cells of the lymph system, part of the body's germ-fighting immune system.
  • Hodgkin lymphoma: A type of lymphoma characterized by the presence of a specific type of abnormal cell called Reed-Sternberg cells.
  • Non-Hodgkin lymphoma: A diverse group of blood cancers that includes all types of lymphoma except Hodgkin lymphomas.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival: The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and excreted by the body.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect.
  • Tolerability: The degree to which side effects of a drug can be tolerated by a patient.

References

  1. http://clinicaltrials.eu/trial/study-on-68gaga-pentixafor-for-detecting-multiple-myeloma-in-patients-under-66-eligible-for-stem-cell-transplantation/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ap707-amitriptyline-and-capsaicin-for-patients-with-chronic-pain-from-diabetic-neuropathy/
  3. http://clinicaltrials.eu/trial/study-on-rituximab-for-patients-with-acute-myocardial-infarction/
  4. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-skb264-and-pembrolizumab-for-patients-with-cervical-urothelial-ovarian-or-prostate-cancer/
  5. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-gen3017-for-patients-with-relapsed-or-refractory-hodgkin-and-non-hodgkin-lymphoma/
  6. http://clinicaltrials.eu/trial/study-of-axicabtagene-ciloleucel-for-patients-with-relapsed-or-refractory-indolent-non-hodgkin-lymphoma/